COLL logo

Collegium Pharmaceutical Inc. (COLL)

$25.55

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on COLL

Market cap

$793977083

EPS

1.02

P/E ratio

17.5

Price to sales

0.89

Dividend yield

--

Beta

0.743939

Price on COLL

Previous close

$25.43

Today's open

$25.14

Day's range

$25 - $25.67

52 week range

$21.43 - $50.79

Profile about COLL

CEO

Vikram Karnani

Employees

423

Headquarters

Stoughton, MA

Exchange

Nasdaq Global Select

Shares outstanding

31075424

Issue type

Common Stock

COLL industries and sectors

Healthcare

Pharmaceuticals

News on COLL

Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

news source

Zacks Investment Research • Nov 17, 2026

news preview

Wall Street Analysts Believe Collegium Pharmaceutical (COLL) Could Rally 81.63%: Here's is How to Trade

The mean of analysts' price targets for Collegium Pharmaceutical (COLL) points to an 81.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

news source

Zacks Investment Research • Nov 10, 2026

news preview

Collegium Pharmaceutical, Inc. (COLL) Q3 2026 Earnings Call Transcript

Collegium Pharmaceutical, Inc. ( COLL ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Ian Karp - Head of Investor Relations Vikram Karnani - CEO, President & Director Colleen Tupper - Executive VP & CFO Conference Call Participants Leszek Sulewski - Oppenheimer & Co. Inc., Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Serge Belanger - Needham & Company, LLC, Research Division Alexander Xenakis - Truist Securities, Inc., Research Division Alexandra von Riesemann - Piper Sandler & Co., Research Division Presentation Operator Greetings, and welcome to the Collegium Pharmaceutical Third Quarter 2026 Earnings Conference Call.

news source

Seeking Alpha • Nov 8, 2026

news preview

Collegium Pharmaceutical Q3 Earnings Call Highlights

Collegium Pharmaceutical NASDAQ: COLL reported record third-quarter 2026 revenue as growth in its attention-deficit/hyperactivity disorder portfolio helped offset declining sales of pain medicines. The company reaffirmed its full-year outlook, though quarterly earnings fell from a year earlier.

news source

MarketBeat • Nov 5, 2026

news preview

Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance

– Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year – – Generated Record JORNAY PM ® Quarterly Net Revenue of $51.9 Million, Up 24% Year-over-Year – – Generated AZSTARYS ® Quarterly Net Revenue of $26.5 Million in First Full Quarter of Sales Under Collegium Ownership – – Generated Quarterly Pain Portfolio Net Revenues of $138.0 Million – – Announced $50 Million Accelerated Share Repurchase in Q3'26 – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass.

news source

GlobeNewsWire • Nov 5, 2026

news preview

Compared to Estimates, Collegium Pharmaceutical (COLL) Q3 Earnings: A Look at Key Metrics

The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Collegium Pharmaceutical (COLL) Tops Q3 Earnings and Revenue Estimates

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.96 per share, beating the Zacks Consensus Estimate of $1.77 per share. This compares to earnings of $2.25 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

COLL or SDZNY: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Collegium Pharmaceutical (COLL) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two stocks offers value investors a better bang for their buck right now?

news source

Zacks Investment Research • Nov 4, 2026

news preview

Earnings Preview: Collegium Pharmaceutical (COLL) Q3 Earnings Expected to Decline

Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Oct 29, 2026

news preview

Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts

New multi-year partnership combines youth coach training, an annual Sports for All Summit, and sensory inclusion programs to support neurodivergent children and families New multi-year partnership combines youth coach training, an annual Sports for All Summit, and sensory inclusion programs to support neurodivergent children and families

news source

GlobeNewsWire • Oct 29, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Collegium Pharmaceutical Inc.

Open an M1 investment account to buy and sell Collegium Pharmaceutical Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in COLL on M1